Wednesday, June 17, 2009

34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence

2009 Awardees Recognized in Amgen Communities Across North America

THOUSAND OAKS, Calif. – June 17, 2009 – Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year’s recipients of the Amgen Award for Science Teaching Excellence. The award recognizes teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the future generation of scientists.

Posted in Philanthropy, Press Releases

Wednesday, June 10, 2009

Statement in Response to FTC Report on Biosimilars

THOUSAND OAKS, Calif.–June 10, 2009–As a biotechnology pioneer committed to developing first-in-class medicines that treat serious illnesses and unmet health needs, Amgen believes that an abbreviated biosimilar approval pathway must not discourage the development of groundbreaking new treatments for serious diseases. 

Posted in Company Statements

Monday, June 08, 2009

New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP

BERLIN – June 7 – Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were presented today as an oral presentation at the 14th congress of the European Hematology Association (EHA abstract #1672).

Posted in Press Releases, Product News